Jessica N. Everett, MS, CGC
Genetic Counselor/Clinic Coordinator, Medical Genetics Clinic

Email: jever@umich.edu

Phone: (734) 763-2532

Campus mail address:
300 North Ingalls
Ann Arbor, MI 48109


Jessica joined the University in 2007 and specializes in cancer genetic counseling. Prior to coming to UM, Jess worked in cancer genetics at the University of Cincinnati. Jess supervises students and teaches components of our cancer genetics class. She is also involved in research related to the provision of cancer genetic counseling and p16 genetic testing.

Research Interests

• Hereditary melanoma – genetic counseling, testing, management
• Hereditary breast cancer – genetic counseling, testing, management
• Clinical application of cancer genetics and genomics


1997 B.S., Biological Sciences, Summa Cum Laude, Ohio University
1999 M.S., Medical Genetics, University of Cincinnati

Board Certification

2002, 2012 American Board of Genetic Counseling Certification

Honors & Awards

1997 Phi Beta Kappa National Honor Society
1997-1998 Graduate Assistantship, University of Cincinnati
1997-1998 Graduate Scholarship, University of Cincinnati
2002 Mead Johnson Excellence in Teaching Award

Selected Publications

Raymond VM, Everett JN. Genetic counselling and genetic testing in hereditary gastrointestinal cancer syndromes. Best Pract Res Clin Gastroenterol, 2009; 23(2):275-283. (PMID 19414152).

Roberts JS, Shalowitz DI, Christensen KD, Everett JN, Kim SY, Raskin L, Gruber SB. Returning individual research results: development of a cancer genetics education and risk communication protocol. J Empir Res Hum Res Ethics, 2010 Sep; 5(3):17-30. (PMID 20831418) PMC 3159194.

Shiovitz S, Everett J, Huang SC, Orloff MS, Eng C, Gruber SB. Head circumference in the clinical detection of PTEN hamartoma tumor syndrome in a clinic population at high-risk of breast cancer. Breast Cancer Res Treat, 2010 Nov; 124(2):459-465. (PMID 20349131).

Christensen KD, Roberts JS, Shalowitz DI, Everett JN, Kim SY, Raskin L, Gruber SB. Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. Cancer Epidemiol Biomarkers Prev, 2011 Mar; 20(3):522-529. (PMID 21307304).

Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med, 2011 Nov 30; 3(111):111ra121. (PMID 22133722)  PMC 3476478.

Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter J, Begg CB, Orlow I, Berwick M, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Culver HA, Rosso S, Zanetti R, Kanetsky PA, From L, Gruber SB. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst, 2012 Jun 20; 104(12):953-956. (PMID 22534780)  PMC 3379723.

Raymond VM, Else T, Everett JN, Long JM, Gruber SB, Hammer GD. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab, 2013 Jan; 98(1):E119-125. (PMID 23175693)  PMC 3537086.

Samadder NJ, Gornick M, Everett J, Greenson JK, Gruber SB. Inflammatory bowel disease and familial adenomatous polyposis. J Crohns Colitis, 2013 Apr 1; 7(3):e103-107. (PMID 22809634).


Updated 5/29/2013